Girard D, Shulman B J, Thys D M, Mindich B P, Mikula S K, Kaplan J A
Anesthesiology. 1986 Aug;65(2):157-64. doi: 10.1097/00000542-198608000-00005.
The safety and efficacy of esmolol during high-dose fentanyl anesthesia were studied in 37 patients undergoing coronary artery bypass grafting (CABG). The anesthetic management consisted of fentanyl 75 micrograms/kg, pancuronium 0.15 mg/kg, and O2. To assess the safety of esmolol, it was administered in a double-blind manner to 17 anesthetized patients prior to surgical incision. Infusion of the drug was increased in stepwise fashion to obtain administration rates between 100 and 300 micrograms X kg-1 X min-1. Esmolol produced small but significant increases in pulmonary capillary wedge pressure (PCWP) (8.3 +/- 1.7 to 13.2 +/- 2.0 mmHg) when compared with placebo (10.9 +/- 1.0 to 12.1 +/- 0.6 mmHg) (P less than 0.05). For the other studied parameters (heart rate, mean arterial pressure, central venous pressure, cardiac index, stroke index, left ventricular stroke work index, systemic vascular resistance, and peripheral vascular resistance), no significant differences were observed between esmolol and placebo. To evaluate the efficacy of esmolol, 20 patients were randomly assigned to an esmolol group (n = 11) or a placebo group (n = 9). The study medication was infused from 5 min before induction through initiation of cardiopulmonary bypass. Infusion of esmolol at 200 micrograms X kg-1 X min-1 prevented tachycardia in response to intubation. In the esmolol group the heart rate increased from 63.4 +/- 2.7 to 67.6 +/- 2.9 beats/min after intubation, while in the placebo group it increased from 61.4 +/- 4.3 to 72.4 +/- 3.4 beats/min (P less than 0.05).(ABSTRACT TRUNCATED AT 250 WORDS)
在37例接受冠状动脉搭桥术(CABG)的患者中研究了艾司洛尔在大剂量芬太尼麻醉期间的安全性和有效性。麻醉管理包括使用芬太尼75微克/千克、泮库溴铵0.15毫克/千克和氧气。为评估艾司洛尔的安全性,在手术切口前以双盲方式给予17例麻醉患者。药物输注以逐步方式增加,以使给药速率达到100至300微克·千克⁻¹·分钟⁻¹之间。与安慰剂组(从10.9±1.0至12.1±0.6毫米汞柱)相比,艾司洛尔使肺毛细血管楔压(PCWP)有小但显著的升高(从8.3±1.7至13.2±2.0毫米汞柱)(P<0.05)。对于其他研究参数(心率、平均动脉压、中心静脉压、心脏指数、每搏指数、左心室每搏功指数、全身血管阻力和外周血管阻力),艾司洛尔组与安慰剂组之间未观察到显著差异。为评估艾司洛尔的有效性,20例患者被随机分配至艾司洛尔组(n = 11)或安慰剂组(n = 9)。研究药物从诱导前5分钟开始输注直至体外循环开始。以200微克·千克⁻¹·分钟⁻¹输注艾司洛尔可预防插管引起的心动过速。在艾司洛尔组,插管后心率从63.4±2.7增加至67.6±2.9次/分钟,而在安慰剂组,心率从61.4±4.3增加至72.4±3.4次/分钟(P<0.05)。(摘要截短于250字)